candidate 113701 (srg) senior biologist

3

Click here to load reader

Upload: jonathan-duckworth

Post on 04-Jul-2015

111 views

Category:

Science


2 download

TRANSCRIPT

Page 1: Candidate 113701 (srg) senior biologist

Submitted by: Jonathan Duckworth Contact Number: 01223 394235 Candidate Name:

Candidate 113701

Location: West Sussex, but looking to relocate to Cambridge

Salary Expectations: £35,000+

Current Role:

Lead Scientist

Desired Role:

Senior Scientist

Notice Period:

Available from late June 2014

Relevant Experience/Skills For Role:

A Senior Cell Biologist with 12 yrs experience in the drug discovery industry, the majority of which have been working on projects for oncology therapeutic targets (PI3K and Protein homeostasis. Very competent in a range of cell biology assays (2D/3D proliferation, migration/invasion) as well as having a strong repertoire of general laboratory skills. In his current role as a lab group head, he is engaged with a number of different discovery project teams where he presents and interprets the data generated by the group to influence project decision making. Actively looking to move to the Cambridge area.

Page 2: Candidate 113701 (srg) senior biologist

C A N D I D A T E 1 1 3 7 0 1

Profile A successful drug discovery scientist with 12 years experience in both small biotech and large pharma setting, working on projects delivering a candidate drugs from the bench to the clinic. Practical cell biology experience investigating small molecule pharmacology in both respiratory disease and oncology research fields. An accomplished communicator with strong analytical skills and a positive approach to team work.

Key Skills Cell Biology

Culture of differentiated near primary bronchial epithelial cells (BECs) in 2D and 3D (bronchosphere) formats

Proliferation, migration and 3D growth assay with oncology cell lines

General Biology

ELISA, Western blotting, Immunofluorescence, confocal microscopy, nucleic acid extraction and gene expression profiling

Software

Spotfire, Graphpad prism, XLfit

Employment History

Novartis Institute for Biomedical Research (NIBR), Horsham UK 2011 – Present Scientist II Leading a small group specialising in respiratory epithelial ion transport – working with differentiated cultures of near primary bronchial epithelial cells to provide high quality screening data for several respiratory disease project teams as well as more bespoke studies for target validation and compound mode of action.

Design and execution of experiments for ion transport drug combinations and validation of literature targets for CFTR modulation

Assessment of a 3D organoid (bronchosphere) culture as a phenotypic screening tool Investigation of the impact of cell culture medium on the differentiation of BECs in air

liquid interface cultures using IF and RNA expression data

Exploratory work on models of live respiratory viral infection of BEC cultures including virus culture (RSV, hRV16, Influenza) and design of a low density Taqman array to probe epithelial host defence response to viral challenge

Working with an academic collaborator to transfer a new technology for increased assay throughput

Active participation in project teams including interpretation of data to facilitate decision making with a 3rd party collaborator

Report writing to support regulatory submissions

2010 – 2011 Scientist I Lab scientist with supervisory responsibility, coordinating the delivery of ion transport data to project teams in the respiratory disease department

Ussing chamber studies with diseased/non-diseased bronchial epithelial cells Generation and presentation of decision making data to support clinical candidate

selection for a respiratory disease project

2009 – 2010 Contract scientist (SRG) Lab scientist working on an ion transport project with a focus on infectious secretory diarrhea

Ussing chamber studies with both engineered and physiologically relevant cell lines

Data analysis and reporting to the project team

Page 3: Candidate 113701 (srg) senior biologist

Piramed Pharma, Slough UK 2007 – 2008 Senior Research Associate Key member of a research team identifying mutation hotspots that could cause resistance to a clinical candidate drug.

Design of resistance selection strategy Optimisation of transfection conditions for retroviral library generation Infection of target cell line and colony selection/expansion for gene sequencing.

2003 – 2007 Research Associate

Member of the cell biology group running a range of in vitro assays supporting compound selection and target validation

In house set-up of cell line based in vitro assays to increase target validation o Migration or invasion through matrigel layer in transwell inserts o Growth of spheroids in semisolid methylcellulose

Sourced and implemented an automated microscopy system to enable quantification of stained tumour sections

Established qRT-PCR capability in house; purchased equipment and developed software skills in micro-array data analysis

Performing proliferation assays (Alamar Blue) in a range of cancer cell lines to support compound progression

Millennium Pharmaceuticals R&D Ltd , Cambridge UK 2001 – 2003 Research Associate Responsibility for running all in vitro enzyme assays for a high priority oncology project. Carried out optimisation and troubleshooting of assays to ensure timely delivery of data for presentation at project team meetings in both UK & US.

Primary target and follow-up selectivity screening in an isolated enzyme HTRF assay Competency in use of lab automation equipment including Multiprobe, Platemate Plus

and Serialmate liquid handling systems

Education 2000 – 2001 University of Nottingham UK

MSc with Distinction: Applied Biomolecular Technology

3 month research placement: Y Chromosome Analysis of the Wirral Population

1996 – 1999 University of Leeds UK

BSc (Hons) 2ii: Biochemistry and Molecular Biology

Publications Raynaud FI, et al Biological properties of potent inhibitors of class I

phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009; 8:1725–38.

Folkes AJ, et al The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer. J Med Chem 2008; 51 (18): 5522-5532

INTERESTS Skiing/snowboarding Woodwork/Furniture making and upholstery